Paul Chin and Matthew Doogue, the authors of the article, comment:
Penny Beirne highlights the inconsistent reporting in the literature of the fraction of unchanged apixaban excreted in urine. This has also recently been noted by others.1a The key article that informed our estimates of apixaban oral bioavailability was a mass balance study.2a It reported that around 25% of an orally administered dose was excreted unchanged in urine. When corrected for an oral bioavailability of 50%, this translates to a fraction of 0.5 excreted unchanged in urine. However, this estimate is made in the absence of data on intravenously administered apixaban.
Since reviewing the literature following this letter, we found another apixaban pharmacokinetic study.3 It reported that the fraction of apixaban excreted unchanged in urine following intravenous administration was 0.34. We thus concur with Penny Beirne and would like to change the apixaban value for ‘excretion unchanged in urine’ in the Table of our article to 34%.
Footnotes
Editorial note: The original article on long-term prescribing of new oral anticoagulants has been corrected based on this letter from the authors.
REFERENCES
-
1a.Hellfritzsch M, Damkier P, Pottegård A, Grønlykke T, Grove EL.
Inconsistencies in reporting of renal elimination among NOACs: the case of apixaban. Pharmacoepidemiol Drug Saf
2016;25:346-8. https://doi.org/10.1002/pds.3916 10.1002/pds.3916 [DOI] [PubMed] [Google Scholar]
-
2a.Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, et al.
Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos
2009;37:74-81. https://doi.org/10.1124/dmd.108.023143 10.1124/dmd.108.023143 [DOI] [PubMed] [Google Scholar]
-
3.Vakkalagadda B, Frost C, Byon W, Boyd RA, Wang J, Zhang D, et al.
Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa. Am J Cardiovasc Drugs
2016;16:119-27. https://doi.org/10.1007/s40256-015-0157-9 10.1007/s40256-015-0157-9 [DOI] [PubMed] [Google Scholar]
